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Abstract
Pulmonary veno-occlusive disease (PVOD) is a rare form of pulmonary hypertension caused by alteration of pulmonary veins. 
Many clinical and hemodynamic similarities to idiopathic pulmonary arterial hypertension (IPAH) may cause diagnostic and 
therapeutic difficulties. This case report is about a patient with PVOD, whose first symptoms of the disease occurred after 
infectious mononucleosis. The patient was administered prostacycline (PGI2) mimetic (Treprostinil), which made qualifica-
tion process and lung transplantation possible. Despite more and more knowledge about the causes, ethiopathogenesis and 
changes in pulmonary veins on molecular level, lung transplantation is the only successful therapeutic option for patients 
suffering from PVOD.
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Introduction
Pulmonary veno-occlusive disease (PVOD) 
is a  rare form of pulmonary hypertension (PH) 
with estimated occurrence of 0.1–0.2 cases per 
million people [1]. PVOD etiology involves pro-
gressive occlusion of small lung veins, which 
causes increased pulmonary resistance and right 
ventricle disfunction [2]. The term PVOD was 
coined by Heath et al. [3], who recognized that 
the disease was a distinct entity from so-called 
“primary pulmonary hypertension” [2]. According 
to the classification system from the Fifth World 
Symposium on PH (Nice, 2013) and the 2015 
European Society of Cardiology (ESC)/European 
Respiratory Society (ERS), which is presented in 
Table 1, PVOD is a subgroup of pulmonary artery 
hypertension (PAH), but its prognosis is worse 
and more serious. Pulmonary edema can occur 
when PAH-specific advanced therapy is adminis-
tered [4, 5]. Most of the cases are identified at an 
early age. The cause of pulmonary veno-occlusive 
disease is unknown, nevertheless, several risk 
factors including infection, chemotherapy and 
medications toxicity, radiation, autoimmunity 
and genetic predisposition are thought to be 
involved [6].
Case presentation
In 2012, 19-year-old male patient was ad-
mitted to the Infectious Diseases Ward, where 
doctors diagnosed him with infectious mono-
nucleosis and interstitial pneumonia. Chest 
X-ray revealed a mark of fluid in the pleural 
cavity. After treatment was initiated, was dis-
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Table 1. Classification of pulmonary hypertension according to European Society of Cardiology/European Respiratory  
Society Guidelines 2015
1. Pulmonary arterial hypertension
 1.1. Idiopathic
 1.2. Heritable
  1.2.1. BMPR2 mutation
  1.2.2. Other mutations
 1.3. Drugs and toxins induced
 1.4. Associated with:
  1.4.1. Connective tissue disease
  1.4.2. HIV infection
  1.4.3. Portal hypertension
  1.4.4. Congenital heart disease
  1.4.5. Schistosomiasis
3. Pulmonary hypertension due to lung diseases and/or hypoxia
 3.1. Chronic obstructive pulmonary disease
 3.2. Interstitial lung disease
 3.3. Other pulmonary diseases with mixed restrictive and obstructive 
pattern
 3.4. Sleep disordered breathing
 3.5. Alveolar hypoventilation disorders
 3.6. Chronic exposure to high altitude
 3.7. Developmental lung diseases




  1′.2.1. EIF2AK4 mutation
  1′.2.2. Other mutations
 1′.3. Drugs, toxins and radiation induced
 1′.4. Associated with:
  1′.4.1. Connective tissue disease
  1′.4.2. HIV infection
 1’’ Persistent pulmonary hypertension of the newborn
4. Chronic thromboembolic pulmonary hypertension and other  
pulmonary artery obstructions
 4.1. Chronic thromboembolic pulmonary hypertension
 4.2. Other pulmonary artery obstructions
  4.2.1. Angiosarcoma
  4.2.2. Other intravascular tumours
  4.2.3. Arteritis
  4.2.4. Congenital pulmonary arteries stenoses
  4.2.5. Parasites (hydatidosis)
2. Pulmonary hypertension due to left heart disease
 2.1. Left ventricular systolic dysfunction
 2.2. Left ventricular diastolic dysfunction
 2.3. Valvular disease
 2.4. Congenital/acquired left heart inflow/outflow tract  
obstruction and congenital cardiomyopathies
 2.5. Congenital/acquired pulmonary vein stenosis
5. Pulmonary hypertension with unclear and/or multifactorial mecha-
nisms
 5.1. Haematological disorders: chronic haemolytic anaemia,  
myeloproliferative disorders, splenectomy
 5.2. Systemic disorders, sarcoidosis, pulmonary histiocytosis,  
lymphangioleiomyomatosis,
 neurofibromatosis
 5.3. Metabolic disorders: glycogen storage disease, Gaucher  
disease, thyroid disorders
 5.4. Others: pulmonary tumoral thrombotic microangiopathy,  
fibrosing mediastinitis, chronic renal failure (with/without dialysis), 
segmental pulmonary hypertension
charged in a good general condition. Since then, 
the patient was feeling progressive dyspnea. 
In 2015, following findings were observed in 
echocardiography: enlarged right ventricle and 
a small diastolic flattening of the intraventricular 
septum (EF: 64%, RV: 28mm, IVS: 9, TAPSE: 23, 
AcT: 85ms). This image suggested elevated pres-
sure in pulmonary arteries. 
In March 2016, he was admitted to the De-
partment of Cardiology for diagnostics of progres-
sive respiratory failure. Medical imaging showed 
linear interstitial diffused lesions in both lungs, 
best defined in costophrenic areas (X-ray) (Fig. 1). 
The most extensive changes localized in the sub-
pleural regions bilaterally (SPECT). His Six-min-
ute walking test (6MWT) result was 510 meters. 
During this test, the patient presented significant 
desaturation of SpO2 level (from 96% to 83%). 
Arterial blood gases (ABG) test revealed respira-
tory alkalosis (pH — 7.468, pCO2 — 31.5 mm Hg, 
pO2 — 72 mm Hg). Echocardiography revealed 
a  small flattening of the intraventricular sep-
tum, a trace of mitral valve incompetence, small 
tricuspid valve incompetence (EF — 77%, RV — 
26 (LAX), IVS — 9 (LAX), AcT — 92 ms, TAPSE — 
20 mm, TVPG — 52 mm Hg, TVI — 361, Vmax of 
tricuspid regurgitation — 361 cm/s). A suspicion 
of pulmonary hypertension was created. During 
his hospital stay, antinuclear antibodies (ANA) 
level was tested — titre was 1:160, but systemic 
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Figure 1. Chest X-ray: Linear interstitial diffused lesions in both lungs
Table 2. Results of test — April 2016
Test Findings
Spirometry FEV1 — 87%, FVC — 77%, 
Tiffeneau index 95.83%
Body plethysmography and DLCO TLC — 90,7%, RV — 126%, RV/TLC 138% DLCO — 60%
6 MWT Distance — 531 m, Borg’s scale — 2, desaturation from 98% to 82%
Right heart catheterization Precapillary pulmonary hypertension, vasoreactivity test was positive
Angio-CT Signs of pulmonary hypertension, widened pulmonary trunk (35 mm), pulmonary arteries and right 
ventricle. Ground glass areas in perihilar region in both lungs, confluent and thickened interlobular 
septa matching pulmonary oedema — image similar to hypersensitivity pneumonitis (allergic  
alveolitis). Both lungs showed nodules (ø4 mm) — probably after pneumonitis; cyst of pericardium 
in costocardiac angle was revealed. There were also enlarged lymph nodes (subcarinal, para-aortic, 
and right hilar)
Nt-proBNP 144 pg/ml
sclerosis was excluded due to video capillaros-
copy of fingers II–IV results in May. There was 
no microangiopathy typical of diseases in the 
systemic sclerosis group. 
In April 2016, body plethysmography, spi-
rometry, heart catheterization, angio-CT of the 
lung arteries and NT-proBNP level were per-
formed. The results are presented in Table 2.
On the base of radiological image (shown in 
Fig. 2), PVOD as the cause of PH suspicion was iden-
tified. Diltiazem was administered, however be-
cause of drug intolerance (bradycardia — 35 beats/ 
/min), treatment was changed to amlodipine (5 mg 
twice a day) with dosage escalation to 10 mg twice 
a day. An improvement of mood was noticed, but 
the therapeutic effect was unsatisfactory.
Figure 2. HRCT: Examination performed before treatment in April 2016
After a week of treatment, fluid levels in both 
pleural cavities were noticed.
In June 2016, treprostinil was added to the 
treatment plan — subcutaneously (amp. 1 mg/ml) 
0.032 ml/h with dosage escalation to 0.034 ml/h 
(9.8 ng/kg/min for 58 kg of body weight). Also, 
furosemide was added to the therapy. A month 
later, the next hospitalization proved that the 
treatment resulted in regression of interlobular 
septa thickening and of pleural fluid accumula-
tion (Fig. 3). A reduction of density and opacities 
in imaging were also noted. Body plethysmog-
raphy, spirometry and ABG results remained 
comparable to ones in April except DLCO, which 
lowered to 34.4%. The administered treatment 
was sustained.
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Figure 3. HRCT: Regression of interlobular septa thickening and of 
pleural fluid after treprostinil therapy
However, the disease was progressing, which 
was noticeable in test results. Decrease in pulmo-
nary function tests (spirometry and bodypletys-
mography), persisting severe decrease of DLCO, 
and reduced 6MWT distance (444 m) with desa-
turation to 83% were noted. Echocardiography 
showed features of serious overload of the right 
ventricle. NT-proBNP level was 444.4 pg/ml.
Hospitalization in the Silesian Center for Heart 
Diseases was scheduled to be in January 2017. Un-
til then, treprostinil’s subcutaneous dosage was in-
creased to 0.048 ml/h (13.25 ng/kg/min for 58 kg). 
Since October, the patient was paying for his 
bosentan treatment (dosage 125 mg twice a day).
During the consult in The Department of 
Cardiac, Vascular and Endovascular Surgery 
and Transplantology, the decision of preliminary 
qualification for lung transplantation was made.
In February, genetic tests confirmed the diag-
nosis of PVOD. Genetic testing showed mutation 
of EIF2AK4 gene, which is responsible for the dis-
ease. Family history seemed to be noncontributory. 
Later that month, the patient was admitted to the 
Department of Cardiology in a very severe gen-
eral condition, with dyspnea during the minimal 
physical effort, hepatomegaly and peripheral 
edema. He fainted several times; hypotension 
and hypoperfusion was noticed. Since the ad-
mission day, progressive increasing of NT-proB-
NP level was observed (up to > 6000 pg/ml). 
During hospitalization, the patient was treated 
with intensive oxygen supplementary therapy, 
furosemide, dopamine and steroids. Treprostinil 
dosage was increased gradually until 26.3 ng/kg/ 
/min was reached. The patient was discharged in 
improved condition, with a recommendation of 
Treprostinil dosage increase and constant oxygen 
therapy.
Next deterioration happened in April. The 
patient was admitted to the hospital with severe 
stomachache, persistent cough and tachycardia. 
He also had an exacerbation of right heart failure, 
present peritoneal signs and signs of multiple 
organ disfunction. There was a need for mechani-
cal circulatory support and forced diuresis with 
intravenous supply of norepinephrine and furose-
mide. Empirical antibiotics, morphine and silde-
nafil treatment were also used. The dosage of Tre-
prostinil was increased simultaneously (74.4 nh/ 
/kg/min), which let the discontinuation of norepi-
nephrine administration and allow to change the 
way of application of furosemide (from intravenous 
to oral administration). A decrease of NT-proBNP se-
rum level was noticeable (from 9135 to 5798 pg/ml). 
The patient was discharged in May in an optimal 
clinical condition with recommendation of con-
stant Treprostinil infusion (74.4 ng/kg/min) and 
consistent oxygen supplementary therapy (3 l/min).
One hundred days after qualification to LT, 
the man was admitted to the Silesian Center for 
Heart Diseases with end-stage circulatory and 
respiratory failure for lung transplantation due to 
the availability of a compatible donor. Uncompli-
cated, orthotopic lung transplantation with a use 
of Extracorporeal Membrane Oxygenation (ECMO) 
was performed. Immunosuppressive maintenance 
therapy including cyclosporine and rapamycin 
was administered. Despite preventive measures, 
the patient showed signs of CMV infection, which 
had to be treated with high doses of antiviral drugs. 
Additionally, the bronchial tree was colonised 
with Burkholderia spp. The man was treated with 
antifungal drugs administered by inhalation and 
oral antiviral medicines. He was discharged after 6 
weeks in good general condition without the need 
for supplementary oxygen therapy.
Two months after LT, during a follow-up ap-
pointment in Silesian Center for Heart Diseases, 
the patient’s state was improving. During 6MWT 
he achieved the distance of 525.5m (Borg’s scale 
— 2, without desaturation). Echocardiography 
showed heart measurements within normal lim-
its, good systolic and diastolic function of the left 
and right ventricle and efficiently working valves 
(EF 66%, TAPSE 23 mm, RVSP 30 mmHg, AcT 
96 ms). There were also no signs of pulmonary 
hypertension. Currently, the patient is alive and 
well 11 months after lung transplantation (Fig. 4).
Discussion
The described case pertains to a young man 
who suffered from progressive physical exercise 
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report an occupational history of significant 
exposure to chemicals such as organic solvents 
(e.g. trichloroethylene). Moreover, the absence of 
exposure to them was associated with a younger 
age of disease and a high prevalence of harbouring 
bi-allelic EIF2AK4 mutations. These findings are 
consistent with our patient’s characteristics. 
Clinical symptoms do not allow to distinguish 
PVOD from PAH. The results of bodypletysmog-
raphy, spirometry, DLCO, or severe hypoxemia 
and decrease in hemoglobin saturation suggest 
rather PVOD than other forms of IPAH. Medical 
imaging using HRCT showed some features that 
may lead to PVOD consideration — ground glass 
opacities, thickened interlobular septa and en-
largement of mediastinal lymph nodes. However, 
these abnormalities in radiological imaging may 
not occur in all of the cases of PVOD and may be 
difficult to see at an early stage of the disease [1]. 
Histopathological examination allows (with the 
highest probability) to confirm the gold standard 
in diagnostic process of the disease. Lung biopsy 
is the diagnostic gold standard. However, it is not 
required due to high risk of complications [2].
The only effective method of PVOD treatment 
is lung transplantation. PAH-specific therapy 
should be used with great caution in PVOD due to 
a high risk of pulmonary edema. However, Mon-
tani et al. assessed that cautious use of continuous 
intravenous epoprostenol improved clinical and 
hemodynamic parameters in PVOD patients at 
3–4 months without commonly causing pulmo-
nary edema, and may be a useful bridge to urgent 
lung transplantation [14]. So was the case when it 
comes to our patient. Such therapy was extended 
only as a bridge to lung transplantation. 
Without the procedure, a mean time of surviv-
al from diagnosis and from first noticeable symp-
toms are 1 year and 2 years, respectively [1, 15]. 
Administering medications that are intended 
for PAH therapy is controversial. Prostacyclin I2 
(PGI2) and its mimetics, such as iloprost and tre-
prostinil have a dilating effect on both pulmonary 
veins and arteries. The study by Benyahia et al. [16] 
suggested that iloprost and treprostinil cause 
similar decrease in human pulmonary arteries’ 
and veins’ resistance, thus they should be the 
most effective clinically available agonists to de-
crease pulmonary vascular resistance and to pre-
vent edema formation. Treprostinil in comparison 
to iloprost has more responsive impact on pulmo-
nary veins. Potential vasodilating effect of using 
PGI2 mimetics in both types of pulmonary vessels 
can be a strong indicator of applying them for 
PVOD treatment [16]. Treprostinil administered to 
Figure 4. Chest X-ray: Extended lung fields, no focal changes, the 
shadow of the heart in a normal shape, visible sutures in both bronchi 
after lung transplantation procedure
intolerance that lasted for a couple of years. The 
beginning of his symptoms was associated with 
mononucleosis infection. 
As the cause of PVOD remains unknown, 
the assumption of multiple risk factors was 
made. Such disease is idiopathic in most of 
the cases. However, there were instances of fa-
milial occurrence and many other factors that 
may cause the outbreak of the disease. One of 
the hypothesis of PVOD pathogenesis is the 
existence of biallelic mutation of EIF2AK4 gene. 
Giererd at al. [7] emphasized the role of this 
mutation in their work. Twelve different fami-
lies (19 people with PVOD) had genetic factor of 
EIF2AK4 mutation. Whereas in the study group 
consisting of 81 patients, biallelic mutation was 
confirmed in 7 (9%) [7]. Genetic tests of the 
described patient detected 2 mutations, both of 
them caused gene inactivation, which is consis-
tent with PVOD diagnosis. Biallelic character was 
not confirmed, but it must be validated in family 
testing. The presented patient is a carrier of re-
cessive mutation in EIF2AK4, which is also char-
acteristic of diagnosis of PVOD. Eyries et al. [8] 
detected the aforementioned mutation among 
individuals with familial and sporadic PVOD. The 
next risk factor described as a prelude to PVOD is 
infection. In many studies there were reports of 
infections caused by flu-like viruses, Toxoplasma 
gondii, measles and Epstein-Barr virus [9–12]. 
It was reported that our patient had a history of 
mononucleosis, which is caused by one of the 
aforementioned viruses. However, to this day, 
this hypothesis was not supported by evidence. 
Montani et al. [13] proved that PVOD patients 
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our patient slowed the progression of the disease 
and let him live until the lung transplantation 
was possible. Before the aforementioned drugs, 
the patient was treated with calcium blockers. 
At the beginning, he received diltiazem, but it 
was not well tolerated. Indeed, it was previously 
observed that this drug could lead to worsening 
among patients with PVOD [17]. Treatment was 
changed to amlodipine with dosage escalation 
to 10 mg twice a day. Even though, this therapy 
did not provide satisfactory results either, there 
was a  case report about a patient with PVOD 
confirmed by biopsy, who presented clinical and 
hemodynamic response to therapy with nifed-
ipine with a significant reduction in pulmonary 
vascular resistance [18]. The use of medications 
dedicated for PAH treatment should be carefully 
considered, and the decision must be well thought 
while taking care of patients with PVOD. 
In conclusion, patients with PVOD require 
thorough diagnostic process in order to properly 
distinguish this disease from pulmonary arterial 
hypertension, as misdiagnosing them as PAH 
could worsen the patients’ condition. Moreover, 
any pharmacotherapy proves to be finally unsatis-
factory in case of PVOD. Lung transplantation 
remains the only therapeutic option for such 
patients. 
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